Compare H1B visa sponsorship data between Asklepios Biopharmaceutical and IBM India Private. See how they stack up on salary, approval rates, and more.

Key Statistics Comparison

Total H1B Filings
9
Asklepios Biopharmaceutical
+100.0%
49,749
IBM India Private
Median Salary
+170%
$250,000
Asklepios Biopharmaceutical
$92,439
IBM India Private
Approval Rate
100.0%
Asklepios Biopharmaceutical
N/A
IBM India Private
Years Sponsoring
4
Asklepios Biopharmaceutical
+75.0%
16
IBM India Private

Historical Trends

H1B Filings Over Time

Asklepios Biopharmaceutical
IBM India Private
2008 2011 2014 2017 2020 2024 1 5,937 11,873

Median Salary Trend

Asklepios Biopharmaceutical
IBM India Private
2008 2011 2014 2017 2020 2024 $60k $167k $275k

Where & What They Hire

Top H1B Job Categories

Asklepios Biopharmaceutical
Regulatory Affairs Managers 1 filings
Compliance Managers 1 filings
Molecular and Cellular Biologists 1 filings
IBM India Private
Computer Systems Analysts 1 filings

Top H1B Work Locations

Asklepios Biopharmaceutical
Acton, MA 2 filings
Research Triangle Park, NC 1 filings
IBM India Private
Piscataway, NJ 1 filings

Year-by-Year Breakdown

Year Asklepios Biopharmaceutical IBM India Private
Filings Salary Approval Filings Salary Approval
FY2024 - - - 1 $92,439 -
FY2023 3 $250,000 100.0% - - -
FY2022 2 $110,000 100.0% 7 $104,829 100.0%
FY2021 2 $106,388 100.0% 49 $96,263 100.0%
FY2020 - - - 293 $92,269 100.0%
FY2019 - - - 1,944 $83,049 99.6%
FY2018 - - - 2,830 $81,837 99.2%
FY2017 - - - 8,368 $77,997 99.5%
FY2016 - - - 9,311 $77,334 99.5%
FY2015 - - - 10,794 $73,965 98.2%
Showing most recent 10 years of 17 total

Frequently Asked Questions

Which company pays higher H1B salaries, Asklepios Biopharmaceutical or IBM India Private?
Asklepios Biopharmaceutical pays higher H1B salaries with a median of $250,000 compared to IBM India Private's $92,439.
Which company sponsors more H1B visas, Asklepios Biopharmaceutical or IBM India Private?
IBM India Private has sponsored more H1B visas with 49,749 total filings compared to Asklepios Biopharmaceutical's 9.

View Full Details